Atea Pharmaceuticals is a clinical stage biopharmaceutical company engaged in discovering and developing therapies to address the unmet medical needs of patients with severe viral diseases. Atea’s lead programs are focused on the development of orally- administered direct acting antivirals for the treatment of patients with COVID-19 in the hospital and community settings, the treatment of patients with chronic hepatitis C infection, the treatment of patients with dengue, and the treatment of high-risk patients with severe respiratory syncytial virus infection. Atea’s medicinal chemistry, virology, and pharmacology expertise, bolstered by their collective experience in drug development, enables them to pioneer new advancements in antiviral science. Leveraging the power of their purine nucleotide prodrug platform, their goal is to rapidly advance novel drug candidates with optimal therapeutic profiles for RNA virus targets.
Bain Capital Healthcare
We have built one of the largest and deepest healthcare investing teams in the world. Click here to read more about the breadth and legacy of our efforts.